16 Spam-Free Article(s) Found
Article Searches
FDA Authorizes Use of Old Malaria Drugs to Treat COVID-19 https://www.fool.com/investing/2020/03/30/fda-authorizes-use-of-old-malaria-drugs-to-treat-c.aspx?source=iedfolrf0000001 Mar 30, 2020 - Despite scant clinical evidence that they work, the FDA issued its first emergency use authorization for therapeutic products to treat the novel coronavirus.
3 Warren Buffett Stocks I Absolutely, Positively Wouldn't Buy Right Now https://www.fool.com/investing/2020/04/05/3-warren-buffett-stocks-i-absolutely-positively-wo.aspx?source=iedfolrf0000001 Apr 05, 2020 - The Oracle of Omaha owns some fantastic stocks in his Berkshire Hathaway portfolio. These aren't in the group.
UBS still bullish on Teva despite trimming fair value target; shares up 9% https://seekingalpha.com/news/3558659-ubs-still-bullish-on-teva-despite-trimming-fair-value-target-shares-up-9?source=feed_sector_healthcare Apr 06, 2020 - In a note, UBS reiterates its Buy rating on Teva Pharmaceutical Industries (TEVA +8.5%) albeit with a revised price target of $12 (from $14).Analyst Kevin Caliendo believes the company is relatively i
Eagle Pharma and Teva prevail in Bendeka patent challenge https://seekingalpha.com/news/3565267-eagle-pharma-and-teva-prevail-in-bendeka-patent-challenge?source=feed_sector_healthcare Apr 28, 2020 - Eagle Pharmaceuticals (NASDAQ:EGRX) and licensee Teva Pharmaceutical Industries (NYSE:TEVA) announce a favorable outcome in a patent dispute from would-be generic competitors to blood cancer med Bende
3 Ridiculously Cheap Buffett Stocks to Buy Now https://www.fool.com/investing/2020/03/31/3-ridiculously-cheap-buffett-stocks-to-buy-now.aspx?source=iedfolrf0000001 Mar 31, 2020 - It's been a while since the Oracle of Omaha had bargains like this in his portfolio.
Teva prevails in migraine patent dispute with Lilly; shares up 9% https://seekingalpha.com/news/3556858-teva-prevails-in-migraine-patent-dispute-lilly-shares-up-9?utm_source=feed_news_all&utm_medium=referral Mar 31, 2020 - The USPTO's Patent Trial and Appeal Board has upheld three patents protecting Teva Pharmaceutical Industries' (TEVA +9.0%) migraine med Ajovy (fremanezumab-vfrm) that were challenged by Eli Lilly (LLY
Teva prevails in migraine patent dispute; shares up 9% https://seekingalpha.com/news/3556858-teva-prevails-in-migraine-patent-dispute-shares-up-9?source=feed_sector_healthcare Mar 31, 2020 - The USPTO's Patent Trial and Appeal Board has upheld three patents protecting Teva Pharmaceutical Industries' (TEVA +9.0%) migraine med Ajovy (fremanezumab-vfrm) that were challenged by Eli Lilly (LLY
2 Crazy-Cheap Buffett Stocks to Buy Now https://www.fool.com/investing/2020/04/13/2-crazy-cheap-buffett-stocks-to-buy-now.aspx?source=iedfolrf0000001 Apr 13, 2020 - Berkshire Hathaway and Teva Pharmaceutical Industries Ltd. are absurdly cheap right now.
Teva launches Ajovy autoinjector in U.S. https://seekingalpha.com/news/3564611-teva-launches-ajovy-autoinjector-in-u-s?source=feed_sector_healthcare Apr 27, 2020 - Teva Pharmaceutical Industries (NYSE:TEVA) announces the availability of the autoinjector device for migraine med Ajovy (fremanezumab-vfrm) at a wholesale acquisition cost (WAC) of $603.20.The
Teva launches Rituxan biosimilar in U.S. https://seekingalpha.com/news/3568193-teva-launches-rituxan-biosimilar-in-u-s?source=feed_sector_healthcare May 04, 2020 - Teva Pharmaceutical Industries (NYSE:TEVA) and collaboration partner Celltrion Healthcare announce the commercial availability of Truxima (rituximab-abbs), a biosimilar to Roche's (OTCQX:RHHBY) Rituxa

Pages: 12

Page 1